Navigation Links
Interim results of VITOBA™ (VImpaT® added to One Baseline AED) Study Presented at the 64th Annual Meeting of the American Academy of Neurology
Date:4/26/2012

ion for infusion), fall, and skin laceration. The use of Vimpat®  is associated with dose-related increase in the PR interval. Adverse reactions associated with PR interval prolongation (e.g. atrioventricular block, syncope, bradycardia) may occur. Refer to the European Summary of Product Characteristics for other adverse reactions and full prescribing information. Date of revision: 21st February 2012.

http://ec.europa.eu/health/documents/community-register/html/h470.htm (Accessed 5th March 2012)

Further Information
Andrea Levin, Associate Director, Communications & PR, CNS, UCB, Inc.
T 770.970.8352 / M 404.483.7329 / Andrea.levin@ucb.com

Dana Gulick, Cooney/Waters Group
T 212.886.2227 / M 917.216.6268 / dgulick@cooneywaters.com

About UCB
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 8,500 people in about 40 countries, the company generated revenue of EUR 3.2 billion in 2011. UCB is listed on Euronext Brussels (symbol: UCB).

Forward looking statements
This press release contains forward-looking statements based on current plans, estimates and beliefs of management. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, political, regulatory or clinical results and other such estimates and results. By their nature, such forward-looking
'/>"/>

SOURCE UCB
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
2. Interim Response and Safety Analyses Support Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma
3. Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
4. Interim Safety Data Favorable for Vicals Phase 2 Trial of DNA Vaccine Against CMV
5. Interim Phase 2 Data for Exelixis XL880 Show Anti-Tumor Activity in Papillary Renal Cell Cancer
6. Leading Physicians Present Interim Results from Multi-Center Studies of VNUS ClosureFAST Catheter at VEITHsymposium
7. Grantees of the Avon Foundation Breast Cancer Prevention Research Initiative Gather in Houston to Report Interim Findings
8. Novavax Announces Favorable Interim Results from Human Clinical Trial for Its Pandemic Influenza Vaccine Program
9. Interim Safety Analysis Supports Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma
10. Interim Analysis Supports Continuation of Cell Genesys VITAL-1 Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer
11. NanoBio Corporation Presents Preclinical and Interim Clinical Data on Topical Treatments for Herpes Labialis and Onychomycosis at AAD 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... September 2, 2015 According to ... Product (Digital & Computed Radiography, Ultrasound, Computed & Optical ... by Application (Oncology, Cardiology, Neurology) - Global Forecast to ... reach USD 2.8 Billion by 2020 growing at a ... Br owse 240 Tables and 44 F ...
(Date:9/2/2015)... and TORONTO ... Corporation ( www.generex.com ) (OTCQB: GNBT) today ... implement a buccal cannabis co-development arrangement with ... been formalized. Generex and CannScience ... Technology Licensing Agreement.  Pursuant to the Agreement, ...
(Date:9/2/2015)... ROCKVILLE, Md. , Sept. 2, 2015 /PRNewswire/ ... "RegeneRx"), a clinical-stage drug development company focused on ... J.J. Finkelstein , President and Chief Executive ... Rodman & Renshaw Global Investment Conference, sponsored by ... will be held September 8-10, 2015 at the ...
Breaking Medicine Technology:Veterinary Imaging Market Worth USD 2.8 Billion by 2020 2Veterinary Imaging Market Worth USD 2.8 Billion by 2020 3Veterinary Imaging Market Worth USD 2.8 Billion by 2020 4Veterinary Imaging Market Worth USD 2.8 Billion by 2020 5Generex Announces Formalization of Buccal Cannabis Co-Development Plan 2Generex Announces Formalization of Buccal Cannabis Co-Development Plan 3RegeneRx to Present at Rodman & Renshaw Global Investment Conference 2RegeneRx to Present at Rodman & Renshaw Global Investment Conference 3
... Tissue Oncology, Society held in Seattle, Washington demonstrates clinical ... single agent in patients with ... chemo-insensitive sarcomas, NEW YORK, Nov. ... preliminary data demonstrating the,tolerability and clinical activity of KRX-0401 (perifosine) in ...
... (ASX: PGL; Nasdaq: PGLA) today announced additional,data from the ... this,year. This data was presented at the 58th Annual ... Diseases in Boston, USA(1). As the Phase 2 ... data analysis described in this presentation was performed to,evaluate ...
Cached Medicine Technology:Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma 2Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma 3Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma 4Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma 5Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma 6Progen Presents Additional Analysis of Data from PI-88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases 2Progen Presents Additional Analysis of Data from PI-88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases 3
(Date:9/2/2015)... Newark, NJ (PRWEB) , ... September 02, 2015 , ... ... as Horizon Blue Cross Blue Shield of New Jersey (Horizon BCBSNJ) donated $11,000 to ... initial $5,000 donation to the foundation at the start of The Barclays, Horizon BCBSNJ ...
(Date:9/2/2015)... ... September 02, 2015 , ... The Hydration ... allopathic medicine, opens its second location this week at 31542 S. Coast Hwy, ... feet of lounge space for patients to relax while receiving safe and effective ...
(Date:9/2/2015)... Appleton, WI (PRWEB) , ... September 02, 2015 ... ... Midwest, Cypress Benefit Administrators is taking action after seeing a significant ... The TPA’s Argus Claim Review division has found many cases of OON ASCs ...
(Date:9/2/2015)... KS (PRWEB) , ... September 02, 2015 , ... Amada ... its newest office in Kansas – its Johnson County location. Amada franchise ... healthcare. Mike has a registered nurse background and spent over 20 years in medical ...
(Date:9/2/2015)... , ... September 02, 2015 , ... ... imaging, content, records and case management solutions and services to both government and ... Image Re-sizing and Image Clean-up utility for IBM’s Datacap document capture platform. ...
Breaking Medicine News(10 mins):Health News:Horizon BCBSNJ’s Healthy Steps Challenge Raises an Additional $6,000 for the NJ Golf Foundation with Help from PGA TOUR Golfer Morgan Hoffmann 2Health News:Horizon BCBSNJ’s Healthy Steps Challenge Raises an Additional $6,000 for the NJ Golf Foundation with Help from PGA TOUR Golfer Morgan Hoffmann 3Health News:The Hydration Room Opens New Location In Laguna Beach, California 2Health News:The Hydration Room Opens New Location In Laguna Beach, California 3Health News:The Hydration Room Opens New Location In Laguna Beach, California 4Health News:TPA Cracks Down on Forbidden Tactics Used by Out-of-Network Surgical Centers 2Health News:TPA Cracks Down on Forbidden Tactics Used by Out-of-Network Surgical Centers 3Health News:Amada Senior Care Expands to Greater Kansas City 2Health News:EDAC Systems, Inc. announces a new version of its Image Enhancement and Image Re-Sizing utility EDAC’s PurePAGE® 2Health News:EDAC Systems, Inc. announces a new version of its Image Enhancement and Image Re-Sizing utility EDAC’s PurePAGE® 3
... venom of the brown recluse spider, researchers at the University ... to open// molecular pores, called ion channels, in the membrane ... Lu, MD, PhD; Yajamana Ramu, PhD; and Yanping Xu, MD, ... venoms from over 100 poisonous invertebrate species to make this ...
... today launched a new vision correction technology, Zyoptix Aspheric, ... ,"There are 60 clinics all across India which use ... be upgraded to Zyoptix Aspherix which further reduces post ... and Lomb India Director-Surgical business Rajat Goel told reporters ...
... like corks to block oxygen flow to tumors, or to ... to a tumor is called embolization, and using gas bubbles ... promising is that the technique allows doctors to control exactly ... to surrounding tissue is minimal, said Joseph Bull, assistant professor ...
... by Dr. Adam Godzik at the Burnham Institute for ... understanding of information gathered// from the human genome project. ... a three year period, this consortium, under the name ... adequate support to scientists from Burnham and UCSD's Computer ...
... labs of Yale Goldman, MD, PhD, Director of the ... of Medicine,// and Erika Holzbaur, PhD, Professor of Physiology, ... show proteins that function as molecular motors are surprisingly ... cell. These observations could lead to better ways to ...
... Once a month osteoporisis drug and extra telephone support from ... among women for their drug treatment// than those who took ... issue of IJCP, the International Journal of Clinical Practice. ... part in the PERSIST study between January 2005 and January ...
Cached Medicine News:Health News:New Way to Open Cellular Ion Channels, Implications for Drug Design 2Health News:Researchers Use Bubbles in Cancer Treatment and Drug Delivery 2Health News:Joint Center for Molecular Modeling Instituted by Burnham Institute for Medical Research & UC San Diego 2Health News:Discovery of Agile Molecular Motors Could Aid in Treating Motor Neuron Diseases 2Health News:Women More Persistent with Monthly Osteoporosis Treatment 2
Coat-A-Count PAP IRMA,is an immunoradiometric assay designed,for the quantitative measurement of,prostatic acid phosphatase (PAP) in,serum. It is intended strictly for in vitro,diagnostic u...
For in vitro diagnostic use,with the IMMULITE 2000 Analyzer for,the quantitative measurement of prostatic,acid phosphatase (PAP) in serum, as an,aid in patient management....
Abbott offers an array of both in-vitro and molecular diagnostic tests for the detection and monitoring of cancerous conditions in patients....
For the quantitative measurement of human prostatic acid phosphatase (PAP) in human serum....
Medicine Products: